A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...

We graduate doctors who appreciate humanistic medicine, concern themselves with the sanctity of human life and commit to dignity and respect for all patients. In short, the medicine we practice is ...